IDEAYA Biosciences, Inc. · NASDAQ:IDYA
IDEAYA Biosciences — Investor Presentation (May 2026)
26 slides from IDEAYA Biosciences's investor presentation, May 2026
Slide 1: Improving Lives Through Transformative Precision Medicines
May 2026 Improving Lives Through Transformative Precision Medicines Corporate Presentation NASDAQ: IDYA
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainti
Slide 3: Vision to Build a Leading Precision Medicine Oncology Company
IDEAYA’s Vision is to Build a Leading Precision Medicine Oncology Company IDEAYA Research and Development Strategy Clinical Pipeline Focus Areas First-in-Class & Darovasertib Best-in-Class Predictive Biomarkers Prolong survival, preserve the Programs eye and vision in uveal melanoma ADC+DDR Combos A
Slide 4: Proven Drug Discovery Engine in Precision Medicine Oncology
IDEAYA’s Proven Drug Discovery Engine in Precision Medicine Oncology Integrated Platform to Deliver Renewable Pipeline of Potential First-in-Class Programs Core IDEAYA Drug Discovery Capabilities 6 internally discovered Candidates delivered clinical stage molecules against difficult-to-drug CRISPR-b
Slide 5: Pipeline Enables Combinations and Targeting of Multiple Solid Tumor Indications
Pipeline Enables Combinations and Targeting of Multiple Solid Tumor Indications Phase 3 / Collaboration Target Indication(s) Phase 1 Phase 2 Potential Registrational partners 1L metastatic UM, HLA*A2(-) + crizotinib1 combination 1L metastatic UM, HLA agnostic + crizotinib1 combination Darovasertib/
Slide 6: Uveal Melanoma is a Rare, Aggressive Form of Cancer with Poor Prognosis
Darovasertib Uveal Melanoma (UM) is a Rare, Aggressive Form of Cancer with Poor Prognosis Patients face severe consequences with limited treatment options at all stages of disease Primary UM Metastatic UM (Localized disease in the eye) (Systemic disease) > 3,000 diagnosed in the U.S. per year ~50% p
Slide 7: Darovasertib Has a Unique Mechanism of Action
Darovasertib Has a Unique Mechanism of Action Targeting the Primary Driver of Disease Activating mutations in GNAQ/11 drive PKC overactivation in nearly all UM patients Primary UM Metastatic UM • UM is biologically distinct from cutaneous Pathway activations by mutations in GNAQ/11 Pathway activatio
Slide 8: Summary of Topline Data from Phase 2/3 OptimUM-02 trial
Summary of Topline Data from Phase 2/3 OptimUM-02 trial Trial met its primary endpoint of statistically significant improvement in median PFS by BICR Statistically significant improvement in median PFS by BICR Median PFS 6.9 months for the darovasertib combination versus 3.1 months (1o endpoint) for
Slide 9: Statistically significant improvement in median PFS by BICR
Statistically significant improvement in median PFS by BICR Darovasertib combination reduced the risk of disease progression by 58% vs. ICT control Kaplan-Meier (KM) Estimate of Progression-Free Survival (PFS)* 1.0 Darovasertib + Crizotinib Investigator Choice Therapy + Censored 0.9 Median PFS in Mo
Slide 10: First Reported Overall Survival with Darovasertib + Crizotinib
First Reported Overall Survival with Darovasertib + Crizotinib Median PFS and OS compared favorably to historical meta-analyses in front-line mUM Median PFS Median OS + Censored + Censored Median PFS (95% CI) Median OS (95% CI) 7.0 Months (3.8, 7.7) 21.1 Months (12.5, 27.1) Survival Probability Surv
Slide 11: Primary Phase Efficacy Results in Neoadjuvant UM
Primary Phase 2 Efficacy Results in Neoadjuvant UM Robust tumor shrinkage leading to eye preservation and visual improvements Cohort 1 (Enucleation) Cohort 2 (Plaque Brachytherapy) Tumor Shrinkage and Eye Preservation Tumor Shrinkage and Visual Improvement 50% 50% 40% Product of Apical Height and La
Slide 12: Darovasertib Potential First Targeted Therapy for All Stages of UM
Darovasertib Has Potential To Be the First Targeted Therapy for All Stages of UM Robust clinical development plan across the uveal melanoma patient journey Diagnosis Primary local therapy Metastasis Progression Primary Uveal Melanoma Metastatic Uveal Melanoma Neoadjuvant Adjuvant HLA*A2-negative HLA
Slide 13: Building a Franchise of TOP1 ADCs to Synergize with IDE161
DLL3 ADC Building a Franchise of TOP1 ADCs to Synergize with IDE161 (PARG inhibitor) Lead ADC product candidate, IDE849, has TOP1 payload and high DLL3 affinity and selectivity Tumor-selective delivery of TOP1 ADC in combination with IDE849 systemic PARG inhibition via IDE161 may synergize to increa
Slide 14: IDE161 Potential to Improve Efficacy and Durability of TOP1 ADCs
IDE161 Has The Potential to Improve Efficacy and Durability of TOP1 ADCs Combination mechanism has shown broad potential across multiple solid tumor models TOP1 inhibitor-induced DNA lesion PARG inhibition by IDE161 maximizes TOP1cc TOP1 ADC payload efficacy Deparylation repair by PARG Cell prolifer
Slide 15: IDE849 (SHR-4849) Demonstrated Initial Efficacy in SCLC
IDE849 (SHR-4849) Demonstrated Compelling Initial Efficacy in SCLC Robust responses observed across multiple expansion doses tested in Phase 1 study * Progressive Disease 2.4 mg/kg 3.0 mg/kg 3.5 mg/kg 4.2 mg/kg Total (≥2.4 mg/kg) 2L Setting All 2L Setting All 2L Setting All 2L Setting All 2L Setting
Slide 16: Phase 1 PFS Data in SCLC Patients Treated with IDE849
Phase 1 PFS Data in SCLC Patients Treated with IDE849 (SHR-4849) Encouraging preliminary evidence of durability across all lines of treatment Total (≥2.4 mg/kg) 2L Setting All (n=42) (n=86) 8 22 Events, n (%) (19.0%) (25.6%) NR 6.7 Median months 3-month rate (%) 93.3% 83.3% 6-month rate (%) 59.0% 55
Slide 17: DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types
DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types ~164,000 potential addressable patients in the U.S. alone Estimated DLL3-Positive U.S. Annual Incidence by Tumor Type 16% 7% ~7K Estimated DLL3+ 72-78% ~6K Frequency by NEC Subtype 11% ~19K Pulmonary 63% ~21K Large-Cell NEC 34% 43%
Slide 18: IDE849 (SHR-4849) Clinical Development Overview
IDE849 (SHR-4849) Clinical Development Overview Potential monotherapy and combination opportunities in multiple DLL3-overexpressing tumors Preliminary Strategy Target Clinical Development Plan • Pursue potential mono- IDE849 therapy AA path in 2L+ Dose Escalation Expansion Cohort: SCLC SCLC and/or 2
Slide 19: IDE034 Potential First-in-Class B7H3/PTK7 TOP1 Bispecific ADC
B7H3/PTK7 ADC IDE034 is a Potential First-in-Class Phase 1 B7H3/PTK7 TOP1 Bispecific ADC Dual tumor-antigen binding to maximize tumor-specific PARG combination benefit in multiple solid tumors αB7H3 αPTK7 Enhanced Tumor Cell Binding vs Robust Linker-Payload Extensive Dual B7H3/PTK7 Surface Protein M
Slide 20: IDE397 Backbone of Combination Strategies for MTAP-Deleted Solid Tumors
MTAP IDE397 is the Backbone of 3 Combination Strategies for MTAP-Deleted Solid Tumors MAT2A is central to support protein methylation and DNA repair in MTAP-/- tumors Combination strategies designed to Chromosome 9 amplify metabolic liabilities and genomic MTAP deletion leads to purines MTA accumula
Slide 21: IDE397 Monotherapy in MTAP-Deleted Lung and Urothelial Cancers
Phase 1 IDE397 Monotherapy in MTAP-Deleted Lung and Urothelial Cancers Best response by RECIST 1.1 at 30mg Phase 2 expansion dose 120% 60% Urothelial Best Response by RECIST (% change from baseline) 40% Adeno NSCLC Squamous NSCLC 20% ^^ PR PR PR PR PR PR PR PR CR 0% # -20% -40% Efficacy by RECIST 1.
Slide 22: IDE892 (PRMT5) Selectivity and Combination Potential with IDE397
PRMT5 IDE892 (PRMT5) Exhibits Robust Selectivity and Combination Potential with IDE397 in MTAP-/- Preclinical Models IDE892 displays positive cooperativity with MTA IDE892/IDE397 combination delivers strong IDE397 enhances a rationally designed PRMT5iMTA and negative cooperativity with SAM on-target
Slide 23: No FDA-Approved Therapies for MTAP-Deleted Solid Tumors
There Are No FDA-Approved Therapies for MTAP-Deleted Solid Tumors IDEAYA’s clinical strategy is focused on lung, urothelial and pancreatic cancers Estimated U.S. Annual Incidence in Priority Tumor Types MTAP-Deletion Frequency by Tumor Type1 Urothelial Cancer 26% ~27K Squamous NSCLC 19% Adeno NSCLC
Slide 24: IDE574 Equipotent Dual KAT6/7 Inhibitor with Broad Potential in Solid Tumors
KAT6/7 IDE574 is an equipotent dual KAT6/7 Inhibitor with Broad Potential in Solid Tumors IDE574: potent dual KAT6/7 inhibitor to overcome paralog bypass Robust mono and combo opportunity across mBC, Lung, and CRC Histone acetyltransferases KAT6A/B and KAT7 collaboratively HR+ mBC NSCLC CRC promote
Slide 25: Building a Leading Precision Medicine Oncology Company
IDEAYA Biosciences: Building a Leading Precision Medicine Oncology Company Clinical stage pipeline advancing across multiple solid tumor indications Anticipated 2026 Pipeline Milestones Highlights Q1 2026 Q2 2026 H2 2026 Darovasertib commercial readiness Metastatic UM (HLA*A2-neg) ✓Metastatic UM (HL
Slide 26: Improving Lives Through Transformative Precision Medicines
May 2026 Improving Lives Through Transformative Precision Medicines Corporate Presentation NASDAQ: IDYA
IDEAYA Biosciences — Investor Presentation (May 2026) on 6ix